Menu Back toExecutives-Respond-to-the-State-of-the-Industry-Report-on-Risk-Based-Approaches-in-Clinical-Trials-Opportunity-or-Threat

DIA 2018 Global Annual Meeting

Executives Respond to the State of the Industry Report on Risk-Based Approaches in Clinical Trials: Opportunity or Threat?

    Session Chair(s)
      Dennis  Salotti, MBA, MS

      Dennis Salotti, MBA, MS

      • Vice President, Operations
      • The Avoca Group, United States
    Part didactic presentation, part lively debate and discussion among an executive panel, dive deep into the state of risk in clinical trials and explore our data on risk assessment and risk-based approaches to clinical trial oversight and execution.
    Learning Objective : Identify the most recent information regarding the state of the industry for familiarity, use, impact and satisfaction with risk assessment and risk-based approaches in clinical research; Develop new perspectives on how to shape their individual and organizational perspectives and positioning with respect to changing regulatory requirements and evolving risk landscape.
      Neil  McCullough


      Neil McCullough

      • Executive Vice President, Clinical Quality and Compliance
      • ICON Clinical Research, United States
      Bari  Kowal, MS


      Bari Kowal, MS

      • Head of Global Clinical Operations
      • Regeneron, United States